Fiscal Year 2020
Funding started by AMED Bridging Research Grant, Seeds A
Reserach on aggregation of 6 kinds of fragment peptides derived from amyloid-β
Screening of 150 synthetic peptides for their aggregation inhibitory effects
Patent application (Kochi University): Japan
Aggregation inhibition and aggregation disengagement peptide
Patent Application 2020-167404 "Amyloid-β aggregation inhibitor, pharmaceutical composition for amyloid-β aggregation disease, and uses thereof”
Reinforcing patent pending
No effect on α-synuclein (Parkinson's disease) or SOD1 (ALS), and specific for Aβ25-35 (Alzheimer's disease)
Verification of pharmacological effects
Cognitive function assessment methods (Y-maze test, open field test, object recognition test, social-behavioral analysis)
Identification of peptides that improve cognitive function in a mouse model of Aβ25-35 intrahippocampal administration
Evaluation of motor function (Rotor Rod)
Identification of peptides that improve motor function in a mouse model of Syn61-84 intracerebroventricular administration
Fiscal Year 2021
Funding continues by AMED Bridging Research Grant, Seeds A
Started screening for ALS and Tau
Patent application (Kochi University): Japan
Aggregation inhibitor, aggregation disengagement peptide
Patent Application 2021-08513 "Amyloid-β aggregation inhibitor, pharmaceutical composition for amyloid-β aggregation disease, and uses thereof"
Patent Application 2021-08512 "Aggregation inhibitor of α-synuclein, pharmaceutical compositions for α-synuclein aggregation diseases, and uses thereof"
Determining dosage and route of administration (research on effects in intranasal administration)
Safety (research on acute toxicity, chronic toxicity, and lethal dose)
Collaboration with companies
BioJapan (booth & matching)
Joint research with domestic companies and a domestic pharmaceutical company
Fiscal Year 2022
Started joint research with a domestic pharmaceutical company and Kochi University for clinical trials.
Fiscal Year 2023
Intranasal administration of our peptides to Alzheimer's disease model mice improved cognitive function.
Intranasal administration of peptides to Parkinson's disease model mice suppressed mobility dysfunction.